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Abstract
Portal vein tumor thrombosis (PVTT) is a common phe-
nomenon in hepatocellular carcinoma (HCC). Compared 
to HCC without PVTT, HCC with PVTT is characterized 
by an aggressive disease course, worse hepatic 
function, a higher chance of complications related to 
portal hypertension and poorer tolerance to treatment. 
Conventionally, HCC with PVTT is grouped together with 
metastatic HCC during the planning of its management, 
and most patients are offered palliative treatment with 
sorafenib or other systemic agents. As a result, most 
data on the management of HCC with PVTT comes 
from subgroup analyses or retrospective series. In the 
past few years, there have been several updates on 
management of HCC with PVTT. First, it is evident that 
HCC with PVTT consists of heterogeneous subgroups 
with different prognoses. Different classifications 
have been proposed to stage the degree of portal 
vein invasion/thrombosis, suggesting that different 
treatment modalities may be individualized to patients 
with different risks. Second, more studies indicate that 
more aggressive treatment, including surgical resection 
or locoregional treatment, may benefit select HCC 
patients with PVTT. In this review, we aim to discuss 
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tumor number, higher tumor grade, worse Child-Pugh 
class and higher serum alpha-fetoprotein (AFP)[7]. At 
the genetic level, next generation sequencing identified 
that mutations of the KDM6A, CUL9, FDG6, AKAP3, 
and RNF139 genes were associated with the develop-
ment of PVTT in advanced Hepatitis B virus-related 
HCC[8]. 
It has to be noted that not all portal vein thrombosis 
in HCC patients is due to neoplastic thrombus. It is 
evident that a portion (ranging from 0.6% to 11%) 
of cirrhotic patients, particularly those with portal 
hypertension, are complicated by non-neoplastic portal 
vein thrombosis (NPVT)[9]. Up to 72.7% of portal 
thrombi in HCC patients are indeed NPVT[10]. Patients 
with NPVT have better prognoses than those with PVTT; 
therefore, the differentiation between NPVT and PVTT 
is of clinical relevance. Theoretically, image-guided 
percutaneous fine needle aspiration or a biopsy of portal 
vein thrombosis could provide a definite pathological 
diagnosis[9,11]. However, biopsy procedures are not 
frequently conducted in clinical practice to confirm PVTT 
because of concerns about life-threatening complications 
such as injuries to the bile ducts or hepatic arteries[11]. 
Instead, non-invasive imaging studies are the most 
frequently used diagnostic tool for PVTT. Contrast-
enhanced ultrasonography, dynamic contrast enhanced 
computed tomography and gadoxetic acid-enhanced 
magnetic resonance could achieve a diagnosis of 
PVTT with sensitivities of 82.5%-98%, 68%-86% and 
92%-95%, respectively[11-13]. 
Conventionally, the treatment algorithm proposed 
by the Barcelona Clinic Liver Cancer (BCLC) system 
considers the presence of PVTT, regardless of the 
degree of invasion, as a contra-indication to surgery 
or transarterial chemoembolization (TACE)[14]. Patients 
with PVTT are classified in the BCLC stage C category 
and are considered candidates for systemic agents. 
However, a recent concept has evolved, which 
considers HCC with PVTT to consist of heterogeneous 
populations with different disease behaviors and 
prognoses, and selected patients with PVTT may 
benefit from more aggressive treatment modalities. In 
the current review, we aim to discuss these changing 
concepts in the management of HCC with PVTT with 
a focus on the latest data on the adoption of a more 
aggressive treatment approach for this disease entity. 
CLASSIFICATIONS OF PVTT 
The management of patients with PVTT can be 
challenging because the clinical course is typically 
characterized by poor underlying liver reserve and 
high portal vein pressure. A complicated operation is 
usually required if an aggressive treatment approach 
is contemplated. To devise the best treatment 
strategy for patients with PVTT, a universally accepted 
classification of PVTT is necessary for the guidance of 
treatment and a comparison of outcomes between 
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the recent conceptual changes and summarize the data 
on the management of HCC with PVTT. 
Key words: Liver cancer; Vascular invasion; Targeted 
agent; Surgery; Radiotherapy 
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Core tip: Conventionally, the presence of portal vein 
tumor thrombosis (PVTT) indicated an extremely poor 
prognosis for hepatocellular carcinoma (HCC) patients 
and was considered a contraindication to both surgery 
and trans-arterial procedures. Recent studies indicate 
that HCC with PVTT represents a heterogeneous 
group with variable prognoses. Several classifications 
have been proposed to gauge the prognoses of 
PVTT. For selected patients with less severe PVTT, 
surgery with curative intent is feasible with favorable 
outcomes. Further, expanding treatment options, 
such as radiotherapy, radioembolization and systemic 
treatment, could improve the outcomes of patients with 
more severe forms of PVTT in patients with HCC. 
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INTRODUCTION
Hepatocellular carcinoma (HCC) is characterized 
by its propensity to invade the vasculature within 
the liver. The invasion of the hepatic vasculature is 
of macroscopic or microscopic type. Macrovascular 
invasion refers to gross invasion into the main portal 
veins or their branches, hepatic veins or the inferior 
vena cava in the liver, while microscopic vascular 
invasion is defined as tumors within a vascular space 
lined by endothelium that is identifiable only by 
microscopy[1]. 
Portal vein tumor thrombosis (PVTT) is the most 
common form of macrovascular invasion of HCC. 
Multiple case series have suggested that the PVTT is a 
common phenomenon with a prevalence rate ranging 
from 10% to over 60%[2-5]. The presence of PVTT in 
patients with HCC has been consistently demonstrated 
by different series to be associated with poor prognoses, 
with a hazard ratio of death close to 2[5,6]. The poor 
prognosis of PVTT in HCC patients is the result of 
combined factors including impaired hepatic reserves, 
intrinsic aggressiveness of tumor, reduced intolerance to 
anti-neoplastic treatment and a high rate of developing 
complications related to portal hypertension. Clinically, 
PVTT is associated with large tumor size, increased 
different groups. At present, various classification 
systems have been developed in different centers. The 
more conventional and better-known classification is 
the one proposed by the Liver Cancer Study Group of 
Japan (LCSGJ). In their General Rules for the Clinical 
and Pathological Study of Primary Liver Cancer[15], 
there is a macroscopic classification of HCC with PVTT: 
Vp0, no PVTT; Vp1, the presence of a PVTT distal to, 
but not in, the second-order branches of the portal 
vein; Vp2, the presence of a PVTT in the second-order 
branches of the portal vein; Vp3, the presence of a 
PVTT in the first-order branches of the portal vein; 
and Vp4, the presence of a PVTT in the main trunk of 
the portal vein or a contralateral portal vein branch 
or both. According to the guideline, resection is one 
of the feasible options for treatment in case of minor 
portal vein involvement (i.e., Vp1 and Vp2)[16]. For 
selected Vp3 or Vp4 patients, surgical resection would 
still be considered, and a 5-year survival of 18.3% has 
been reported[16]. In view of the guarded prognosis, 
few centers would adopt this aggressive approach. 
Moreover, the required expertise is not always available 
(Table 1).
In 2007, Shi et al[17] devised a classification of 
HCC with PVTT that incorporated microscopic PVTT 
as Type 1. In this classification, Type 1 is a PVTT 
involving segmental branches or above; Type 2 is a 
PVTT involving the right or left portal vein; Type 3 is 
a PVTT involving the main portal vein; and Type 4 
is a PVTT involving the superior mesenteric vein. In 
general, surgical resection can be applied to Type 3 
and to selected patients with Type 4. In their report, 
the numbers of patients with Types 1, 2, 3 and 4 
were 144 (32.7%), 189 (42.9%), 86 (19.5%) and 22 
(5.0%), respectively. The 1-, 2-, and 3-year overall 
survival rates were 54.8%, 33.9% and 26.7% for Type 
1 patients, respectively, 36.4%, 24.9% and 16.9% for 
Type 2 patients, respectively, 25.9%, 12.9% and 3.7% 
for Type 3 patients, respectively, and 11.1%, 0% and 
0% for Type 4 patients, respectively (P < 0.0001).
A simplified classification by Xu et al[18] divided 
patients with PVTT into two groups: Group A, with 
involvement of the main portal vein trunk or both 
the left and right portal veins, and Group B, with 
involvement of only the left or right portal vein. In 
their report, the Group A 1-year overall survival rate 
was 31.5% after resection, and the 1-, 3- and 5-year 
overall survival rates of Group B patients were 62.3%, 
16.1% and 5.2%, respectively. This simple classification 
could be used as a quick reference when counseling 
patients (especially Group A patients) about surgical 
treatment. No matter which of the above classifications 
is used, the prognosis would be determined by the 
extent of the PVTT and its proximity to the main, or 
even the contralateral, portal vein.
SURGERY (EN BLOC PORTAL 
VEIN RESECTION VS TUMOR 
THROMBECTOMY) 
The prognosis is notoriously poor for HCC patients with 
macrovascular PVTT, especially those whose PVTT has 
extended to the main or contralateral portal vein[19]. 
The PVTT could propagate further and obstruct the 
whole vein lumen, resulting in liver failure or life-
threatening variceal bleeding. One of the treatment 
modalities is surgical resection, the two common 
modes of which are tumor thrombectomy and en bloc 
resection of the thrombus and the portal vein followed 
by portal vein reconstruction. Tumor thrombectomy 
is technically less demanding but might result in a 
residual tumor. As for the latter mode, it is associated 
with high morbidity and mortality rates despite a 
“perceived” better oncological outcome[20]. However, 
there has been no randomized controlled trial to 
determine the superiority of one over the other, and 
the choice rests with individual centers and individual 
surgeons (Figure 1).
A PVTT confined to the hepatic lobe harboring 
the HCC (ipsilateral PVTT) is usually resected when a 
hepatectomy is conducted to remove the HCC[21]. For 
the management of PVTT extending to the portal vein 
bifurcation or the main or contralateral portal vein, 
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Table 1  Common classifications of portal vein tumor thrombosis in hepatocellular carcinoma
Group Types of PVTT Survival
Ikai et al[80] Vp0: Absent 59% at 5 yr
Vp1: Distal to but not in second-order branches 39.1% at 5 yr
Vp2: In second-order branches 23.3% at 5 yr
Vp3: In first-order branches 18.3% at 5 yr (Vp3 and Vp4)
Vp4: In the main trunk or contralateral or both
Shi et al[17] 10: Microscopic
1: In segmental branches or above 26.7% at 3 yr (Type 10 included)
2: In the left or right branch 16.9% at 3 yr
3: In the main trunk 3.7% at 3 yr
4: In the superior mesenteric vein 0% at 3 yr
Xu et al[18] A: In the main trunk or both the left and right branches 0% at 5 yr
B: In only the left or right branch 5.2% at 5 yr
HCC: Hepatocellular carcinoma; PVTT: Portal vein tumor thrombosis.
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liver transplantation at this center certainly contributed 
to the low morbidity rate after portal vein resection[24]. 
The 1-, 3- and 5-year overall survival rates were 
50%, 12.5% and 12.5%, respectively, in Group 2 and 
28.6%, 14.3% and 14.3%, respectively, in Group 3. 
The 1-year disease-free survival rates were 24.3, 0, 
and 14.3%, respectively. The 3-year DFS rates were 
14.3, 0, and 14.3%, respectively. The 5-year DFS rates 
were 10.7, 0, and 14.3%, respectively. Again, the two 
approaches had no significant differences in terms of 
overall survival or disease-free survival. Patients with 
ipsilateral PVTT also had similar survival outcomes 
compared with patients with PVTT extending to or 
beyond the bifurcation. These survival outcomes were 
satisfactory when compared with those (a median 
survival duration of only 2.7 mo) of patients with PVTT 
who were untreated[1]. Peng et al[25] compared hepatic 
resection and transarterial chemoembolization (TACE) 
for patients with PVTT and found that the resection 
group had significantly longer overall survival. The 
1-, 3-, and 5-year overall survival rates were 42.0%, 
14.1% and 11.1%, respectively, in the resection group 
and 37.8%, 7.3% and 0.5%, respectively, in the TACE 
group (P < 0.001). In the subgroup analysis, the 
resection group had better overall survival in regard to 
Type 1 PVTT, Type 2 PVTT, single tumor, and tumor >5 
cm (P < 0.001, P = 0.002, P < 0.001, and P < 0.001, 
different approaches have been recommended. En 
bloc resection, including bifurcation with or without the 
main portal vein and/or the contralateral portal vein, 
is believed to produce good oncological outcomes[22]. 
However, it has been documented that thrombectomy 
can produce similar survival outcomes with lower 
operative mortality and morbidity[20-22]. In a study from 
Japan, 979 consecutive patients were evaluated, and 
45 of them had Vp3 or Vp4 PVTT[23]. They received 
hepatectomy with tumor thrombectomy. The 3- and 
5-year survival rates in the Vp3 and Vp4 groups 
were 35.3% and 41.8%, and 21.2% and 20.9%, 
respectively.
In a study by The University of Hong Kong trying 
to address the controversy about en bloc resection 
vs thrombectomy[21], patients were divided into 
three groups: Group 1 (n = 71), with ipsilateral PVTT 
resected in a hepatectomy; Group 2 (n = 10), with 
PVTT extending to or beyond the bifurcation, treated by 
en bloc resection followed by portal vein reconstruction; 
and Group 3 (n = 7), with PVTT extending to or beyond 
the bifurcation, treated by thrombectomy. The median 
overall survival duration was 10.91 mo in Group 1, 9.4 
mo in Group 2, and 8.58 mo in Group 3, and it was 
shown that en bloc resection and thrombectomy were 
not significantly different in terms of hospital mortality 
and morbidity. The frequent practice of living donor 
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Figure 1  Schematic diagrams demonstrating different types of portal vein tumor thrombosis and the relevant surgical approaches. A: Thrombectomy; B: En 
bloc resection with portal vein reconstruction. RPV: Right portal vein; LPV: Left portal vein; MPV: Main portal vein. Courtesy of Chok et al[21].
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respectively). No difference in overall survival was 
shown in regard to Type 3 PVTT, Type 4 PVTT, multiple 
tumors, and tumor < 5 cm (P = 0.541, P = 0.371, P = 
0.264, P = 0.338, and P = 0.125, respectively).
In a number of reports concerning all degrees of 
PVTT, the median survival durations varied from 8.9 mo 
to 33 mo, and the operative mortality rates varied from 
0% to 5.9%[22,26-30]. For patients with PVTT confined to 
the ipsilateral first-generation portal vein, resection of 
the PVTT in a hepatectomy is recommended. With a 
good resection margin, intrahepatic recurrence could 
be prevented. For PVTT extending to or beyond the 
bifurcation, an en bloc resection or thrombectomy 
should be considered. Nonetheless, if the liver is 
cirrhotic or if the resection would leave an inadequate 
liver remnant, major resection will not be possible.
TRANS-ARTERIAL 
CHEMOEMBOLIZATION 
Trans-arterial chemoembolization takes advantage 
of the relatively selective arterial vascularization of 
hepatic tumors. Chemotherapeutic agents are delivered 
with simultaneous embolization to increase the local 
chemotherapeutic dwell time and induce tumor 
ischemia[31]. The technique of TACE varies; typically, 
super-selective cannulation of the artery supplying the 
tumor is performed whenever possible. An emulsion 
of cisplatin (1 mg/mL) and Lipiodol (Lipiodol Ultrafluide®; 
Laboratoire Guerbet, Aulnay-Sous-Bois, France) in 
a volume ratio of 1:1 is injected up to a maximum 
of 60 mL, depending on the size and number of the 
tumor[32,33], with or without embolization. TACE is 
repeated every 8 to 12 wk, and the treatment is to be 
stopped when there is progressive disease, extrahepatic 
disease, a severe life-threatening complication, or 
evidence of liver failure or decompensation (serum total 
bilirubin > 50 μmol/L, gross ascites with uncontrollable 
with diuretics, or hepatic encephalopathy)[34]. TACE 
is considered the primary treatment for patients who 
have inoperable HCC that is confined to the liver and 
in the absence of contraindications to TACE. Studies 
have reported that 35% of patients had a complete or 
progressive response to TACE, with < 2% of patients 
having a complete response[35,36]. Lo et al[37] compared 
TACE with symptomatic treatment and found that the 
patient survival rate at 2 years after treatment was 
higher with TACE (41%) than that with symptomatic 
treatment (27%). 
The thought behind using TACE for the treatment 
of HCC with PVTT is evolving. Traditionally, TACE is 
generally not recommended for patients with PVTT 
because of the increased risk of liver failure[38,39], 
but there have been no large trials to validate this 
recommendation. For the past 5 years, a growing 
number of studies showed that TACE could be safely 
conducted in patients with PVTT, provided that there 
is an adequate hepatic reserve and the establishment 
of collateral blood circulation around the obstructed 
PVTT (Table 2)[40,41]. Of note, there are two randomized 
prospective studies comparing TACE to conservative 
management in patients with PVTT. Both studies 
consistently demonstrated improved overall survival in 
the TACE arm when compared to patients undergoing 
conservative management. Both studies have also 
conducted subgroup analyses in a population with 
different degrees of PVTT. Niu et al has shown that 
the survival benefits in PVTT type 1 (TACE: 19 mo vs 
conservative: 4 mo, P = 0.001); type Ⅱ (TACE: 11 mo 
vs conservative: 1.43 mo, P < 0.001); type Ⅲ (TACE: 
7.1 mo vs conservative: 1.3 mo, P < 0.001) and type 
Ⅳ (TACE: 4 mo vs conservative: 1 mo, P = 0.005). 
Luo et al showed that the 6-mo survival rates of the 
TACE arm for branch and main PVTT were 75% and 
38.7%, respectively, compared to 45.5% and 20% 
in the conservative arm. There are also prospective 
studies comparing TACE vs the hepatic arterial infusion 
of chemotherapy, of which superior survival outcomes 
were observed in the TACE arm. 
Currently, there are no prospective data from a 
head-to-head comparison between TACE and systemic 
therapy in patients with PVTT. However, taking the 
above studies into consideration, it is generally 
accepted that TACE is feasible and effective in select 
patients with branch PVTT because the overall survival 
appeared to be longer than that achieved in most 
clinical trials of systemic therapy. As shown in Table 2, 
many more Child-Pugh A patients underwent TACE, 
and the benefits of TACE were significantly less in Child-
Pugh B patients with PVTT. Liver function remains the 
most important criteria for selecting patients to receive 
TACE treatment. The role of TACE in the treatment of 
main PVTT (Vp4 or type Ⅲ/Ⅳ) is more controversial. 
Although randomized studies indicated the survival 
benefits of TACE in these groups of patients, overall 
survival (4-7 mo) was similar, if not inferior, to survival 
observed in clinical trials on systemic agents such as 
sorafenib (see below: systemic therapy). 
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Table 2  Prospective trials on transarterial chemoembolization 
for hepatocellular carcinoma with portal vein tumor thrombosis
Group No. of 
patients
Treatments Child-Pugh 
A
Survival
Luo et al[81] 164 
(84 vs 80)
TACE vs 
Control
Not known 1-yr survival 30.9% 
vs 9.2%
Niu et al[82] 150 
(115 vs 35)
TACE vs 
Control
88 vs 21 Median survival 
8.67 mo vs 14 mo
Kim et al[83] 110 
(49 vs 61)
TACE vs 
TACI
30 vs 22 Median survival 
14.9 mo vs 4.4 mo
Peng et al[25] 603 
(402 vs 201)
TACE vs 
Resection
389 vs 197 Median survival 
42 mo vs 14.1 mo
TACE: Transarterial chemoembolization; PVTT: Portal vein tumor 
thrombosis; TACI: Transcatheter arterial chemoinfusion.
Chan SL et al . Management of HCC with PVTH
RADIOTHERAPY
External radiotherapy 
Historically, external radiotherapy (RT) is not considered 
a feasible treatment in the management of HCC. This 
is because the liver is highly radiosensitive, and the 
delivery of a sufficient high dose RT without excessive 
hepatotoxicity is challenging. However, as a result of 
the advances in RT technology, including the conformal 
RT planning and breathing motion management and 
image-guided radiation therapy, RT has emerged as 
a valid treatment option in the treatment of HCC[42,43]. 
A number of retrospective studies have studied the 
efficacy of RT as single treatment or in combination 
with other treatment modalities, particularly TACE, in 
treating HCC with PVTT (Table 3). These reports have 
consistently reported a favorable toxicity profile and 
modest efficacy of RT[44-57]. In one of the largest series, 
412 patients with PVTT were treated with 21-60 Gy 
in 2- to 5-Gy fractions in combination with sequential 
TACE. The median survival was 10.6 mo with a 2-year 
survival rate of 23%, while grade 3 or above toxicity 
was observed in 10% of patients[44]. The radiologic 
response of PVTT to RT is the most significant pro-
gnostic factor, with a median overall survival of 19.4 
mo in the responder group vs 7.0 mo in the non-
responder group. 
There is also a growing body of evidence suggesting 
that the concurrent administration of RT and locoregional 
treatment could improve the response rate or treat-
ment outcomes of PVTT. In a retrospective study 
reported by Zhang et al[45], patients with PVTT were 
treated with percutaneous transhepatic PV stenting 
and TACE, with or without RT. The median overall 
survival was 16.5 mo in the RT cohort compared with 
4.8 mo in the non-RT cohort. In a matched cohort 
study by Katamura et al[46], a significant improvement 
in the objective response rate in PVTT was observed 
in the RT group compared with the non-RT group 
(75% vs 25%) in patients treated with intra-arterial 
5-fluorouracil and interferon-alpha. Several studies had 
evaluated the dose-response of RT in the treatment 
of HCC with PVTT. The response rate was better 
when the biologically effective dose (BED) exceeded 
58 Gy[47,48,50]. Therefore, an attempt to deliver a BED 
as high as possible is preferred during the planning 
of RT to HCC with PVTT. However, this can only be 
achieved in cases of small primary HCC, where both 
HCC and PVTT could be covered within a high dose 
target volume without compromising the normal liver. 
In clinical practice, because bulky HCC is frequently 
encountered, a combined approach with RT to focus on 
PVTT and TACE for the treatment of the intra-hepatic 
tumor is generally preferred to keep the normal liver 
radiation tolerance within a safe limit. Well-designed 
prospective studies are required to evaluate this 
combination for patients with PVTT. 
Selective internal radiation therapy 
Selective internal radiation therapy (SIRT), or tran-
sarterial radioembolization with Yttrium-90, involves 
the transarterial administration of therapeutic doses 
of radiation to the hepatic tumor via resin or glass 
particles. Although resin and glass are both considered 
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Table 3  Studies on radiation therapy for hepatocellular carcinoma with portal vein tumor thrombosis
n Treatment Total RT dose/
fractional dose (in Gy)
Response rate 
(CR + PR, %)
Median 
survival (mo)
Toxicity grade ≥ 3 (%) Ref.
45 3D-CRT 
(+TACE/PEI/RFA; 7% RT only)
38-65/1.8-2.5 62.3 (CR 6.7) 11.2 2 Rim et al[51]
412 3D-CRT + TACE 21-60/2-5 27.9 (CR 3.6) 10.6 10 Yoon et al[44]
40 IGRT + IA 5FU/IFN vs IA 5FU/
IFN
30-48/7-16 60 (CR 5) 12 (RT) 15 Chuma et al[52]
9.1 (non-RT)
32 IA 5FU/IFN + 3D-CRT vs IA 5FU/
IFN
30-45/3 75 (CR 19) 7.5 (RT) G4: 2 Katamura et al[46]
7.9 (non-RT) G3: 7% (leucopenia)/
6% (thrombocytopenia)/
1 (anorexia)
45 PV stenting + TACE + 3D-CRT vs 
PV stenting + TACE
30-60/2 35.6 (CR 0) 16.5 (RT) 0 Zhang et al[45]
4.8 (non-RT)
326 3D-CRT (IMRT 14.1%) 60/2-3 18.1 (CR 5.8) 4 0 Huang et al[53]
38 3D-CRT 17.5-50.4/1.8-4 44.7 (CR 15.8) 9.6 0 Toya et al[47]
59 3D-CRT 30-54/2-3 45.8 (CR 6.8) 7.8 0 Kim et al[48]
44 RT + TACE 36-60/2 45.5 (CR 34.1) 8 0 Kim et al[49]
19 3D-CRT (+ TACE for liver tumor) 46-60/2 57.9 (CR 0) 7 G3: 5% (thrombocytopenia)/
2% (leucopenia)/
2 (GI ulcers)
Yamada et al[54]
20 RT + TACE 50/2 50 (CR 0) 5.3 5 Ishikura et al[55]
24 RT + TACE 50/2 50 (CR 16.7) CR/PR (9.7) 13% Tazawa et al[56]
NR/PD (3/8)
281 3D-CRT + TACE 30-54/1.8 -4.5 53.8 (CR 3.6) 11.6 20% Yu et al[57]
3D-CRT: 3 dimensional conformal radiotherapy; GI: Gastrointestinal; PR: Partial response; RT: Radiotherapy; TACE: Transarterial chemoembolization; NR: 
Non-responder; PD: Progressive disease; PVTT: Portal vein tumor thrombosis.
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permanent embolic agents, their embolic effects are 
less than those of a TACE procedure due to their small 
size, as is their effect on hepatic vascular dynamics[58]. 
During radioembolization, a radioactive microsphere 
is selectively injected into the hepatic artery or its 
branch, delivering intense local tumor radiation. SIRT 
provides adequate radiation to the tumor with little 
radiation to the rest of the liver and to the patient’s 
body. Because it does not cause ischemia, SIRT can 
be performed in patients with portal vein thrombosis, 
making SIRT a feasible choice for HCC with PVTT. 
Common complications of SIRT include fatigue and 
deranged liver function[59]. Serious complications such 
as radiation pneumonitis, radiation cholecystitis, liver 
abscess and radiation-induced liver disease occur in 
less than 1% of patients. In general, technetium-
labeled macroaggregated albumin scanning is 
performed prior to SIRT to quantify the fraction of lung 
shunting and/or the tumor/normal uptake ratio. The 
accepted safe radiation dose to the lung is less than 30 
Gy in a single procedure and less than 50 Gy in total 
over multiple procedures[59,60]. 
Studies on SIRT focusing on patients with HCC and 
PVTT are limited. However, numerous retrospective 
series have reported the safety and efficacy of SIRT in 
patients with HCC[61-64]. Subgroup analyses from the 
three largest series of HCC patients who underwent 
SIRT involving more than 200 patients with PVTT 
demonstrated the overall survival to be approximately 
10 mo. Ozkan et al[65] reported a better median overall 
survival of 17 mo among 29 HCC patients treated with 
SIRT, with and without PVTT. There was no significant 
difference in survival between patients with and 
without PVT. A report from the largest group of PVT 
patients showed concordant results[63], in which it was 
also found that patients with Child-Pugh A cirrhosis, 
with or without PVT, benefited the most from SIRT. 
In a recent prospective phase Ⅱ trial of 35 patients 
with PVT treated with SIRT, the overall survival of 
Child-Pugh A and B patients were 16 mo and 6 mo, 
respectively. 
The efficacy of SIRT in unresectable HCC was 
compared with sorafenib in a recent study. Edeline 
et al[66] retrospectively reviewed the records of 151 
HCC patients with PVTT. The overall survival of 
34 patients treated with SIRT was compared with 
117 patients treated with sorafenib only. SIRT was 
associated with a higher median overall survival 
compared to sorafenib (18.8 mo vs 6.5 mo, P < 
0.001). A prospective randomized study comparing 
SIRT and sorafenib has already completed accrual with 
preliminary results expected to be available in late 
2016 (NCT01135056). At present, there have been no 
randomized controlled trials directly comparing SIRT 
to TACE in patients with HCC and PVTT. Several small-
scale studies have suggested that the efficacy of SIRT 
is comparable to TACE in unresectable HCC. Of note, 
She et al[67] performed survival analysis of 16 patients 
who underwent SIRT and compared it with another 
16 patients in a matched cohort treated with TACE. 
Half of the patients in each group had major vascular 
invasion, and those treated with SIRT had an overall 
survival of 12.0 mo compared to 8.0 mo in the TACE 
cohort. These data provide preliminary clues that SIRT 
might be more effective than TACE in the setting of 
HCC with PVT, but this hypothesis requires further 
validation in prospective randomized clinical trials. 
SYSTEMIC THERAPY 
Compared to other cancer types, the progress in 
the development of systemic therapy is slower for 
HCC. Conventional cytotoxic chemotherapy, such as 
doxorubicin or doxorubicin-based combinations, could 
lead to significant toxicity, which limits the potential 
benefits in cirrhotic populations[68]. Other more “novel” 
regimens of systemic chemotherapy have also been 
evaluated. In particular, the combination of oxaliplatin 
and 5-fluorouracil and leucovorin, known as the 
FOLFOX4 regimen, has been compared to doxorubicin 
in patients with advanced HCC in an Asian population 
with HCC[69]. The overall study fails to demonstrate 
a statistically significant difference between the two 
regimens, but FOLFOX4 was found to have small 
survival benefits in the subgroup population of Chinese 
patients[70,71]. There have been a handful of case 
reports or series showing that cytotoxic chemotherapy 
could improve the severity of PVTT, but there are no 
dedicated prospective studies to validate such efficacy 
of systemic chemotherapy in the treatment of PVTT. 
Further, the toxicity of systemic chemotherapy has 
been shown to be higher in the presence of impaired 
liver function and portal hypertension, which frequently 
occur in patients with PVTT. 
Sorafenib is a multi-targeted small molecule with 
specific activity against vascular endothelial growth 
factor receptor. Its use in the setting of BCLC stage 
C HCC, including patients with PVTT, extra-hepatic 
metastases, and ECOG performance status of 1 or 
higher, is known to modestly prolong median overall 
survival by approximately 2 mo, compared to a 
placebo[72,73]. In both Phase Ⅲ clinical trials, namely the 
SHARP[72] and the Asian pacific study[73], there are no 
detailed analyses on the efficacy of sorafenib according 
to the different severities of PVTT. Nevertheless, the 
efficacy of sorafenib in PVTT may still be indirectly 
reflected by the subgroup analyses in patients with 
macrovascular invasion. In both studies, the proportion 
of macrovascular invasion in the sorafenib arm was 
36%, and subgroup analyses unanimously indicated 
similar survival benefits between patients with and 
without macrovascular invasion[72,73]. Regarding the 
specific treatment for patients with Vp3 and Vp4 PVTT, 
a retrospective review was published by a Korean 
center, which analyzed the outcome of sorafenib in 6 
patients with Vp3 and 24 patients with Vp4 PVTT[74]. 
It was shown that 10% (3 patients) had a partial 
response in the PVTT arm with revascularization, and 
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the median overall survival was 3.1 mo. The above 
dataset suggested that sorafenib demonstrated a 
modest efficacy in the treatment of PVTT, but given 
the low response rate of likely lower than 10%, the 
treatment is mainly reserved as a palliative treatment 
for patients with Vp3 or Vp4 who are not amenable to 
more aggressive treatment.
Recently, the direction of the development of 
systemic treatment for HCC has shifted from targets 
along signaling pathways to immunotherapy and, 
in particular, to the check-point inhibitors. There 
have been one phase I clinical trial of a cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4) inhibitor, 
tremelimumab, and another ongoing trial on a 
programmed cell death protein-1 (PD-1) inhibitor, 
nivolumab, in patients with advanced HCC[75,76]. Both 
studies have suggested that check-point inhibitors 
are tolerable and potentially efficacious in HCC. In 
particular, some remarkable and durable radiological 
responses have been observed. Given the more 
mature and robust data of the immune check-point 
inhibitor in the treatment of HCC, its use in the 
treatment of PVTT can be better elucidated. Another 
direction is biomarker-driven drug development, which 
aims to improve the response via patient selection with 
predictive biomarkers in the tissue or plasma[77]. 
PORTAL VEIN STENTING
Theoretically, the placement of an endovascular stent 
into the portal vein could increase the portal blood flow 
into the liver parenchyma in HCC complicated with 
PVTT. This may, in turn, relieve the portal hypertension-
related complications, especially variceal bleeding, 
and expand treatment options for the tumor. Most of 
the studies on portal vein stenting in the treatment 
of PVTT of HCC are case reports or small-scale series. 
Two large-scale case series suggest that portal vein 
stenting is feasible in select patients. One series come 
from a Japanese group that reported the percutaneous 
placement of stents in the portal vein following the 
administration of TACE or trans-arterial infusion of 
chemotherapy in 21 patients[78]. With a 100% success 
rate of placement, it was demonstrated that the portal 
pressure decreased by approximately 3 mmHg. A short 
course of an anticoagulant was administered in 14 
patients, but it was not suitable for the others due to 
coagulopathy. The patency rate was 53.6% at 1 year 
with a mean patency period of 12.4 mo. Procedure-
related complications appeared to be uncommon, with 
only a case of pseudoaneurysm reported. Another 
large case series from a French group reviewed the 
records of 54 patients with PVTT who underwent portal 
stenting under general anesthesia by a percutaneous 
approach or an open approach via catheterization of 
the superior mesenteric vein after exteriorization of the 
terminal ileum[79]. Twenty percent of patients developed 
complications after portal stenting, mostly in the form 
of hepatic failure, and 7% died within 30 d of stenting. 
Bilirubin levels > 30 μmol/L and an open surgical 
approach were predictors of short-term mortality. TACE 
was administered in 48% of patients after stenting, and 
the 12-mo survival rate was 44%. Both of these series 
indicate that the placement of portal stents is a feasible 
procedure with potential efficacy. However, because 
of the concern of bleeding complications during the 
anticoagulation period and the potential risk of tumor 
dissemination during the stenting procedures, in 
addition to the complicated procedures involved, portal 
vein stenting has not gained wide acceptance among 
HCC experts.
FUTURE PERSPECTIVES
The need for high-level evidence  
Conventionally, HCC with PVTT is considered to be an 
advanced disease with clinical management similar 
to HCC with extra-hepatic metastases. There are 
no dedicated clinical trials to study the treatment of 
this population. As a result, the efficacy and safety 
of different treatment modalities on PVTT are mainly 
generated from retrospective studies or extrapolated 
from subgroup analyses of prospective clinical trials. 
Currently, it is evident that the prognoses and disease 
behavior of patients with PVTT differ from those of 
patients without PVTT. In addition, patients with PVTT 
are more prone to develop complications due to portal 
hypertension or hepatic failure. Therefore, to define 
a better treatment strategy for patients with HCC 
with PVTT, dedicated clinical trials in this population 
are warranted. Because the prognoses differ between 
patients with different severities and degrees of PVTT, 
it is important to accurately gauge the outcome of 
patients during the design of clinical trials for HCC with 
PVTT. To achieve this goal, a uniform classification of 
PVTT is required for the stratification of risk groups 
during randomization and to facilitate the comparison 
of results between different studies. At present, at 
least three classifications have been developed for 
PVTT in HCC. It is crucial to reach consensus on the 
classification of PVTT amongst the HCC experts. 
Multi-disciplinary approach 
Management of HCC with PVTT is a clinical dilemma 
with challenges. On one hand, despite the recom-
mendation of sorafenib as the standard treatment 
for HCC with PVTT by the BCLC guidelines, emerging 
evidence clearly shows that select patients could benefit 
from more aggressive treatment approaches. On the 
other hand, not all patients may uniformly benefit from 
aggressive treatment. PVTT represents an adverse 
prognostic factor with an underlying more rapid disease 
course. Aggressive treatment may not lead to better 
outcomes in some patients; for example, in the setting 
of poor performance or with impaired hepatic function. 
Therefore, when facing patients with HCC with PVTT, 
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clinicians have to balance the potential benefits 
and toxicity of different treatments in the individual 
patients. A multi-disciplinary tumor board is required 
to determine the most appropriate management 
of patients with PVTT. Furthermore, the cumulative 
evidence indicates that a single treatment modality is 
unlikely to achieve a remarkable effect in PVTT, and 
the combination of different treatment modalities, 
such as RT to PVTT and TACE or the addition of SIRT 
to systemic agents, may be more efficacious in select 
patients. Future research should focus on combinations 
of different established treatment modalities for PVTT 
in HCC. 
CONCLUSION
The management of HCC with PVTT is evolving. 
The treatment modality for HCC with PVTT includes 
surgical resection, TACE, radiation therapy including 
external RT or SIRT of the liver lesions, and systemic 
agents, while portal vein stent treatment remains 
investigational. Dedicated clinical studies on HCC 
complicated with PVTT are inadequate. The decision of 
the optimal treatment for individual patients requires 
multi-disciplinary input. Future research should be 
geared towards the generation of high-level evidence 
of novel treatments and combinations of established 
treatments for this population. 
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